State Medicaid home and community-based waiver programs for persons with AIDS (PWAs) were implemented with the expectation that PWAs would use home and communitybased services in lieu of more expensive hospital-based care. If so, then Medicaid spending per PWA should decline and this in turn should generate program cost savings. While some published research indicates that waiver participants incur lower expenditures than nonparticipants, this evidence is based on data which pre-dates the development of highly effective but expensive antiretroviral combination therapies. In this study, we analyzed Florida Medicaid claims data for PWAs from December 1995 through December 1997 to determine how participation in the home and community-based waiver affects the use of inpatient services, the receipt of antiretroviral combination therapies, monthly expenditures and survival of PWAs.
I.

Introduction
The prognosis, survival and quality of life for persons living with HIV/AIDS (PLWHAs) have improved dramatically in recent years due to the development of highly active antiretroviral drug therapies (Palella, et al., 1998; Hogg et al., 1998) . Concomitantly, advances in medical treatment have enabled the majority of PWLHAs to obtain care on an outpatient basis or in their home. Currently, state Medicaid programs are the primary payers of medical care services for PLWHAs. To illustrate, Medicaid spending on care for PLWHAs amounted to about $3.3 billion in 1997, compared to $1.3 billion by Medicare and around $1.2 billion under the Ryan White CARE ACT ( Sambamoorthi et al., 1999) . In an effort to control increasing Medicaid expenditures, yet simultaneously provide high quality care, a number of state Medicaid programs implemented home and community-based waiver initiatives for persons with AIDS (PWAs) during the early 1990s. Initially authorized under section 2176 of OBRA 1985, the Medicaid 1915c waiver enables states to expand the array of home and community-based services that are available to Medicaid beneficiaries with AIDS. Waiver services are regarded as an add-on, that is, an additional bundle of 15 to 20 services such as meals-on-wheels, personal care services, or chores that are not available to beneficiaries under the traditional Medicaid program. The presumption behind this initiative is that if home and community-based waiver services are used in lieu of inpatient services then waiver participants should incur lower expenditures than non-waiver participants, and State Medicaid programs should realize cost savings.
This presumption is questionable for at least two reasons. First, empirical evidence from evaluations of home-care waiver programs for elderly Medicare beneficiaries suggests that home and community-based care tends to complement rather than substitute for inpatient services and thus results in higher costs per beneficiary (Lindsey, Jacobsen and Pascal, 1990) . Second, although AIDS-specific waivers are currently functioning in 16 States, only a few published studies have evaluated the impact of waiver enrollment on utilization of services, monthly patient expenditures and outcomes (Anderson and Mitchell, 1997; Merzel et al., 1992; Crystal, Sambamoorthi and Lo Sasso., 1998; Mitchell and Anderson, 2000) . These studies found that monthly expenditures and use of inpatient services are lower for waiver participants than for either a control group of non-waiver participants or the entire population of PWAs.
Nonetheless, with the exception of the recent study by Mitchell and Anderson (2000) , these studies are based on data which pre-date the development of highly effective antiretroviral therapies for the treatment of HIV/AIDS. Thus, it is unclear whether home and communitybased waiver initiatives for PWAs are able to generate cost savings in this era of highly effective but expensive drug treatment regimens.
In this study, we analyze Florida Medicaid eligibility and claims data for PWAs spanning the years 1996 through 1997 to evaluate how participation in the Medicaid waiver program for PWAs affects the types of services received by patients, monthly patient expenditures, and health. Importantly, antiretroviral combination therapies were available to Medicaid recipients with AIDS throughout the time period. First, we examine whether persons who choose to participate in the waiver program in Florida are more or less likely to receive antiretroviral combination drug therapies and inpatient care. Second, we also examine whether waiver enrollment has any impact on monthly patient expenditures and survival. Considering that the waiver offers a bundle of home and community based services that are not readily available to other Medicaid beneficiaries with AIDS, we expect to find significant differences in the types of services used by waiver participants in comparison to those not enrolled in the waiver. These services may be viable alternatives to costly inpatient care. We do not know, however, whether waiver patients are more or less likely to receive recent combination drug therapies and whether the overall treatment packages differentially affect survival and/or monthly patient expenditures.
The remainder of this paper is organized as follows. The second section provides a brief synopsis of the relevant literature. Section three describes the data, sample inclusion /exclusion criteria and variable construction. Section four outlines the estimation strategy. In section five we report the results. A final section contains concluding remarks.
II. Literature Review
Empirical evaluations of Medicare home and community-based waiver initiatives for elderly persons suggest that home and community-based services tend to complement rather than substitute for institutional care and thus result in higher costs per beneficiary (Lindsey, Jacobson and Pascal, 1990) . However, this conclusion may not be applicable to home and communitybased waivers designed for PWAs for at least three reasons. First, previous research failed to account for the possible non-random selection of home and community-based services in evaluating the impact of the waiver on costs. Second, waiver initiatives for the elderly were designed to deter the use of nursing home care. In contrast, services available under AIDSspecific waivers are supposed to substitute for more expensive inpatient care. Finally, the elderly and AIDS populations differ with respect to demographic composition, services received and disease duration. This suggests that findings based on elderly populations are probably not applicable to PWAs (Weissart, Cready and Pawalek, 1988) .
The limited research that has evaluated the effects of enrollment in AIDS-specific home and community-based waiver initiatives suggests that these programs yield cost-savings. For example, Merzel et al. (1992) examined the New Jersey waiver experience and estimated average monthly treatment costs per Medicaid enrollee of $2,400 in 1988; they concluded that the average costs for PWAs enrolled in the waiver were substantially lower than the $5,000 monthly estimate suggested by previous studies. In a more recent yet unpublished study, Crystal, Sambomoorthi and LoSasso (1998) also examined the impact of the New Jersey
Medicaid home and community-based waiver program on the costs of care, use of inpatient and outpatient services, and access to care. Their multivariate analyses based on Medicaid data for PWAs diagnosed between 1988 and 1992 show that New Jersey waiver participants utilized substantially fewer inpatient services and more outpatient services in comparison to those receiving traditional care, yet there was no difference in overall monthly costs of care between the two groups. Further, waiver participation appears to reduce socioeconomic differences in access to outpatient services. Using more recent data from the New Jersey AIDS waiver, Sambamoorthi et al. (1999) compared the use and costs of home-care between waiver and nonwaiver enrollees. Their findings suggest that waiver participation appears to reduce racial and risk group differences in the probability of using home care, although injection drug users were less likely to participate in the waiver. Irrespective of waiver enrollment, injection drug users incurred significantly lower monthly home-care expenditures.
The only other evaluations of Medicaid AIDS-specific waiver compare participants and non-participants in Florida. Anderson and Mitchell (1997) found that, after controlling for program selection, PWAs enrolled in the home and community-based waiver in Florida during its first two years of operation (1990) (1991) , incurred monthly Medicaid expenditures that were 22-27% lower than non-participants. Using more recent data for the years 1993 through 1997, Mitchell and Anderson (2000) evaluated the effects of waiver participation and recently developed antiretroviral drugs on monthly expenditures for Florida Medicaid recipients with AIDS. They found that, after controlling for gender and race/ethnicity, monthly Medicaid expenditures for non-waiver participants were significantly higher than for waiver enrollees.
The major reason for the cost difference is that non-waiver enrollees incurred higher inpatient costs than PWAs enrolled in the waiver. Although waiver participants incurred higher drug expenditures, these drug costs represent only a fraction of the higher inpatient costs incurred by non-waiver enrollees. While their analyses are the first to evaluate the impact of the recently developed AIDS drugs on patient costs, they provide only indirect estimates because they examined a time period that includes three years prior to and two years after the availability of combination therapies. To directly measure the impact of the new antiretroviral therapies on patient costs, one should focus solely on the time period during which these drug treatments were available. Furthermore, their more recent analysis is descriptive and thus does not control for the waiver selection and other confounding factors.
Our study attempts to address the limitations of existing research by examining the effects of waiver participation on the use of services, monthly patient expenditures and survival during a time period when the antiretroviral combination therapies were available to Medicaid recipients.
III. The Data and Sample Construction
The data for this research came from records of Medicaid claims for medical services in The first recorded claim for a combination drug therapy among the patients who meet these criteria occurs in December 1995. Because we are interested in differential access to these therapies, we further limit our analysis to only PWAs who entered the Medicaid program prior to December 1995 and survived through December 1995. Hence, our analyses are only based on claims filed for services rendered to individuals when combination therapies were available throughout the period. After making these exclusions, the final sample includes 10,836 PWAs enrolled in the Florida Medicaid program.
B. Variable Construction
For each person in our database, we have records for each month in which a claim for Medicaid services is filed. Each record contains information about the claim as well as basic demographic information about the patient. Claims information includes the number and types of services provided, pharmaceuticals prescribed, amounts paid by Medicaid for services and drugs, diagnosis codes and date of death. Demographic information includes age, race, gender, and county of residence. We have no information on diagnosis codes prior to January 1993; we, therefore, cannot determine the month in which they are first diagnosed with HIV or AIDS if they are on Medicaid prior to January 1993. We also have no information on income or employment of recipients and their families at any point in time. We construct proxy measures from information on county per capita income and county urbanization.
We collapse the claims records for each person so that we have one record per person.
This file contains information on waiver enrollment and our three categories of dependent variables -treatments received, expenditures, survival -and our independent variables.
Utilization is Waiver participation is a dummy variable equal to one if the patient was enrolled in the waiver during the patient's last month in the data. Those persons who were not enrolled in the waiver also had at least one claim for inpatient care at some point between January 1993 and December 1997. This is an appropriate control group because the waiver is only available to PWAs deemed to be at risk of hospitalization.
The exogenous variables in our models include demographic characteristics, community characteristics, and stage of disease. The demographic characteristics are: race, gender, age at first claim, and county characteristics for county of last claim. Race/ethnicity is measured with two dummy variables for black or Hispanic; white is the omitted category. Gender is a dummy variable equal to one if the patient is female. Age is measured in years. County characteristics include median per capita income and percentage of the county population residing in urban areas. In the waiver selection and input choice models, we also control for other characteristics of the county which influence the choice of home and community-based care: pharmacies per Medicaid patient, home health care agencies per population, and hospices per population.
We do not have laboratory data with which to measure the severity of AIDS in each patient. However, the claims record contains detailed diagnosis information which we used to construct three indicators of patient health. We measure the state of health at the beginning of our analysis period -December 1995. This state of health at the start of the period is, therefore, exogenous to the choice of the waiver and the types of services received during the 1996-1997 period.
The first health variable attempts to capture the severity of AIDS. Using the information reported in the diagnosis code field on each claim, we extract the 32 AIDS defining diagnoses identified by HIV/AIDS physicians; these diagnoses were employed in the screening algorithm developed by Medicaid program staff. We construct 32 dummy variables indicating whether the PWA ever had a diagnosis of each condition prior to December 1995. We then assumed that these indicators (I) are jointly and linearly related to the latent AIDS health outcome (A) as follows: I = A B' +  where B is a vector of weights and  is random error. We employed factor analysis to construct an index A based on estimation of this model. This index proxies for severity of disease, with higher values representing greater severity. The factor loadings and the scoring coefficients for these AIDS health indicators for the first common factor are given in Appendix Table A The second health variable is designed to reflect the presence of other comorbidities. To control for other comorbidities, we construct a series of 15 dummy variables to identify the following broad categories of health conditions: infectious disease, malignant neoplasm, immunity problem, blood disease, nervous system disorder, circulatory problem, respiratory problem, pneumonia (not AIDS related), digestive system problem, genitourinary problem, skin problem, musculoskeletal problem, drug dependency, other symptoms as yet undiagnosed, and injuries. We have many reported diagnoses from the first claim through December 1995. We collapse all of these reported diagnoses over the 1993-1995 period into dummy variables. To develop an index of "Other Comorbidities", we again employ factor analysis. In this case, I
above is the set of indicators of Other Health problems. We extract the first common factor from this analysis and use this as our measure of Other Health. The factor loadings and scoring coefficients are reported in Appendix Table A .2.
Third, we construct a separate dummy variable to identify women who were pregnant at some point during the three year time period before December 1995. This variable is equal to one if a female PWA was ever pregnant during 1993-1995 and is equal to 0 if she was not pregnant or if the PWA was male.
IV. Empirical Models
In this section we describe the models that we use to estimate the effect of waiver participation on treatments received, expenditures and survival. We assume that participation in the waiver by PWAs is not random so that the residuals in a waiver choice model would be correlated with the residuals in the treatments received, expenditure and survival models. Careful modeling of the choice of the waiver is critical in order to obtain unbiased estimates of the effect of waiver enrollment on either treatments received, expenditures or survival. The first step in our analysis is, therefore, to estimate a model of waiver participation.
We assume that waiver participation (W), and therefore the treatments received, are affected by the characteristics of the patient and the availability of comparable services in the community. The characteristics of the patient (X) include race, gender, age, and health. The vector X also includes measures of county income and urbanization to proxy for household resources. The variables which identify selection of the waiver include the availability of pharmacies, hospices, and home health care agencies in the county (Z). The empirical constructs for X and Z are described above. We expect to find greater waiver participation in urban areas and higher income counties than in other counties relative to rural areas and lower income counties. We also expect to find lower enrollment in the waiver if the county has many available home and community-based alternative services such as hospices, home health care agencies and pharmacies. These organizations would be able to provide more information and more choices for patients in the absence of Medicaid waiver services. We estimate the model of waiver participation using probit analysis.
Our analysis evaluates the effect of waiver participation on two types of services: the use of inpatient care (H) and the receipt of combination drug therapies (D). H and D are affected by patient and community characteristics (X) and by participation the waiver (W). Because D and H are each dichotomous variables, we estimate two simultaneous probit models. The first estimates selection of the waiver (W) and the use of inpatient care, while the second estimates waiver enrollment and receipt of combination drug therapies (Maddala, 1983) We first estimate reduced form models of waiver selection (W), use of inpatient care (H) and the receipt of combination therapies (D). We then estimate the probability of waiver selection from the reduced form and use this estimate in structural models of use of inpatient care (H) and receipt of combination therapies (D). Given that choice of the waiver is associated with a different package of services compared to those available under traditional care, or both simultaneous probit equations, we rely on nonlinearities to identify the model.
The next model we estimate is the log of monthly expenditures. We estimate both OLS and IV models; the latter recognizes that waiver participation is an endogenous right-hand side variable. In the expenditure model, we use the availability of hospice care in the county, home health agencies per population in the county and pharmacies per Medicaid recipient in the county as identifying variables.
The health outcome of interest is patient survival (S), measured as the number of months alive from December 1995 through December 1997. S is assumed to depend on the characteristics of the patient (X) and the selection of the waiver (W). We estimate three models of survival. In the first model, we estimate a model of log duration (log S) using standard regression. We assume, in this model, that waiver selection is exogenous. In the second model, we control for the endogeneity of waiver participation and estimate the log duration model using instrumental variables estimation. The instrument for waiver participation is the predicted probability of participation W* obtained from the probit model of waiver participation described above. Waiver participation is identified through the measures of the relative availability of hospice, home health agencies and pharmacies in the county of residence.
The regression model of log duration does not control for the probability that the patient has an incomplete lifetime by December 1997. To allow for censoring, we also estimate our survival using a Weibull hazards model. In the Weibull model, h 0 (the baseline hazard) is assumed to be equal to pt
; if p is greater than one, then the hazard increases with duration or the probability of death increases over time. The waiver variable in the hazard model is the predicted probability of waiver participation derived from the probit model. Table 1 reports descriptive statistics for all PWAs and then stratifies the sample by waiver participation. About half of the 10,836 persons in the sample are enrolled in the waiver.
V. Empirical Results
A. Descriptive Evidence
As anticipated, use of services varies significantly between waiver and non-waiver enrollees.
Waiver participants are much more likely to use combination drug therapy (59%) compared to only 25% of non-waiver enrollees. The reverse holds for inpatient care; close to 35% of waiver participants use inpatient care compared to almost 66% of non-waiver participants. These differences in the use of services have implications for expenditures. On average, expenditures during the two year period are $1290 a month among all patients. After controlling for waiver enrollment, it appears that average monthly expenditures of waiver participants are $1622 compared to $961 for non-waiver participants. This significant difference in monthly expenditures is linked to differences in the services provided to patients in the two groups.
Monthly expenditures on drugs are about $600 higher among waiver participants while their expenditures on inpatient care are only $150 lower. These differences explain most of the observed differential in average expenditures between the two groups of patients.
Between 1996-1997, about 17 percent of these patients die, and the average survival time is 22 months. We find that waiver participants are more likely to die before December 1997 than non-waiver participants and non-waiver participants live, on average, two months longer than waiver participants; 22 percent of waiver participants die during the interval and 12.5 percent of non-waiver participants die. However, based on our indices of health, we find that waiver participants are in worse health and are much less likely to have been pregnant. This suggests that sicker patients are selecting the waiver program, and this selection may be driving the mean differences in survival that we observe.
As regards race/ethnicity, about 42 percent are black, 8 percent are hispanic, and 50 percent are white. Women account for 47 percent of PWAs. The average age of patients is 38, and over 80 percent report living in urban areas of their counties. Waiver and non-waiver participants differ in these demographic characteristics. Waiver participants are more likely to be white and male than non-waiver participants. Only 26% of waiver participants are female compared to 67% of non-waiver participants. The majority of waiver participants are white (58%) compared to 43% of non-waiver enrollees. Waiver participants are about 3 years older on average than non-waiver participants and are more likely to live in urban areas.
The descriptive evidence indicates that the waiver is not randomly selected by patients but is more likely to be chosen by white men and sicker patients than is traditional care. This suggests that some groups of PWAs -in particular, women and blacks -may have less information about the waiver option and its relative benefits. We also find evidence that receipt of combination drug therapies, use of inpatient care, expenditures and survival vary by waiver status. Whether participation in the waiver actually does increase expenditures and lower survival cannot be determined from these descriptive results, however, because we have not as yet controlled for the differential effect of health and individual patient characteristics on these outcomes. The results of our multivariate analyses which control for the non-random selection of the waiver option on use of services, expenditures and survival are reported below.
B.
Probit Estimates of Waiver Selection, Combination Drug Therapy, and Inpatient Care white men are more likely to choose the waiver than other demographic groups. We also find that the higher the severity of the AIDS condition as measured by our AIDS health index, the more likely the PWA is to join the waiver. Persons with a higher score on the Other
Comorbidites index and women who have been pregnant are less likely to enroll. The effect of
Other Comorbidities on waiver selection is much weaker than the effect of AIDS severity.
Community characteristics are also important to the selection of the waiver. The waiver is more likely to be chosen by PWAs residing in wealthier counties in Florida. We also find that PWAs who reside in counties with greater availability and access to home health agencies and pharmacies are less likely to join the waiver. The reverse holds for PWAs who reside in counties with greater access to hospice care. While these findings suggest that home health services and pharmacies are substitutes for waiver services, it appears that hospice services may be complementary with waiver care.
Using these estimates of waiver participation, we next evaluate the effect of the waiver on the type of care received by patients. In particular, we estimate the impact of waiver participation on the receipt of combination drug therapies and the use of inpatient care. From Table 2 , we find that there are significant effects of waiver participation on the type of care received. Waiver participants are significantly more likely to receive combination drug therapy but are significantly less likely to receive inpatient care relative to non-waiver participants. This suggests that waiver services are a substitute for inpatient care yet they appear to be complementary to the receipt of antiretroviral drug therapy. These results are significant and are consistent with the descriptive statistics in Table 1 .
We find that both the receipt of drug therapy and inpatient care vary with demographic characteristics and patient health status. In the reduced form and structural models, women are less likely to receive combination drug therapies but are more likely to be hospitalized than men, after controlling for health. Blacks are more likely to receive combination drug therapies than whites, although racial differences in the receipt of inpatient care received by PWAs once we control for waiver participation are negligible. Health is also an important determinant of the types of services that each patient receives. Patients with more severe cases of AIDS are more likely to obtain the combination drug therapies, although severity of AIDS has no impact on the use of inpatient care. Patients who score higher on the Other Comorbidities index and women who have ever been pregnant are less likely to receive either drug therapy or inpatient care.
County characteristics also have some impact on the care received. Patients in counties with more hospice care are less likely to receive combination therapy or inpatient care while patients in counties with more home health agencies are more likely to receive both drug therapy and inpatient care. Pharmacy availability is associated with a lower probability of inpatient care, yet it has no impact on the odds of receiving combination therapy.
C. Waiver Enrollment and Average Monthly Expenditures
To determine whether the waiver is a less expensive treatment option than standard care, we next examine the costs of this treatment per month using Medicaid expenditures as our measure of cost. The expenditure models are presented in Table 3 . We find that waiver enrollment has a positive effect on monthly costs if we assume that participation in the waiver program is exogenous. However, when we control for non-random participation in the waiver program by PWAs, we find that the waiver enrollment results in lower average monthly Medicaid expenditures. After adjusting the coefficients to account for the log dependent variable, the OLS results suggest that waiver enrollees incur monthly expenditures that are 68.5 percent higher than non-participants. In contrast, the IV results imply that monthly patient expenditures are 49 percent lower for waiver participants relative to non-participants. We also find, as expected, that expenditures are lower for women on average. Racial differences in monthly Medicaid expenditures are negligible. Sicker patients, using either index of health, are more expensive patients as expected, but women who have been pregnant are much less costly than either men or other women in our sample. Expenditures are also higher in more urban areas of the state and in counties with higher income. These community results are consistent with expectations. Table 4 presents the results from the estimation of regression and hazards models of survival. Three models are presented in this table: OLS regression assuming waiver selection is exogenous, instrumental variables regression (IV) controlling for non-random participation in the waiver and a Weibull hazards model. The coefficients in the regression models are marginal impacts on log duration (survival from Decembe 1995 -December 1997 . For the hazard model, we report the odds ratios derived from the hazard model coefficients. An odds ratio greater than one indicates that the independent variable increases the probability of death, whereas an odds ratio less than one means the odds ratio is associated with a lower probability of death.
D. Waiver Enrollment and Survival
We find that waiver participation, irrespective of whether it is exogenous, endogenous or a predicted probability, has no effect on survival in either the regression or the hazard models.
Thus, although waiver participants use a different package of services than their non-waiver counterparts, these differences in treatments received have no impact on survival. The descriptive statistics suggest that PWAs enrolled in the waiver survive about one month less than non-wavier participants. However, these mean differences do not control for differences in the other characteristics of patients that may explain survival differences. Once we control for differences in other patient characteristics, we find no effect of waiver participation on survival.
The survival results in combination with the finding that waiver enrollees incur lower monthly expenditures than non-waiver enrollees suggest that services available under the AIDS-specific waiver yield a significantly more cost-effective form of treatment than services available to nonwaiver enrollees under the traditional Medicaid program.
Contrary to waiver enrollment, some patient characteristics are linked to differences in survival. Blacks have lower survival and a higher odds of dying then other patients. Conversely, women are less likely to die than men. We also find that sicker patients as measured by both the AIDS index and the Comorbidity index, are significantly more likely to die than less sick patients.
We find, however, a protective effect of pregnancy among women. Women who were ever pregnant prior to December 1995 were less likely to die during the 1996-1997 period. Finally, the odds of dying appear to be significantly higher in urban areas..
V. Conclusions and Policy Implications
Some state Medicaid agencies implemented AIDS-specific home and community-based waiver programs during the late 1980s and early 1990s to provide home and community-based services to PWAs as an alternative to more expensive hospital-based care. If home and community-based care is used in lieu of more expensive inpatient care, then Medicaid expenditures per AIDS patient should fall and this in turn should generate program savings.
Although some published research has demonstrated that participants in AIDS waivers incur lower monthly expenditures than non-participants (Anderson and Mitchell, 1997; Merzel et al.; 1992) , these studies are based on data from a time period which pre-dates the availability of recently developed antiretroviral combination therapies. In this study, we analyzed Florida
Medicaid claims data for PWAs during the period December 1995 through December 1997 to evaluate the effects of waiver participation on use of inpatient care, receipt of combination drug therapies, monthly expenditures and survival. Importantly, antiretroviral combination therapies were available to Florida Medicaid recipients with AIDS throughout this time period.
Our findings indicate that the waiver program offers a different form of treatment to PWAs; waiver enrollees receive home-based care, less inpatient care, and have greater use of combination drug therapies. The waiver is not randomly selected by eligible patients, however.
White men and persons who have greater AIDS related severity are more likely to enroll in the waiver program than other patients.
Recognizing that waiver participation is a choice and thus must be modeled as an endogenous right-hand side variable has significant implications for the analyses evaluating the impact of waiver participation on monthly expenditures. After controlling for non-random selection of the waiver program through instrumental variables estimation, waiver patients are found to incur significantly lower expenditures per month than non-waiver patients. The IV estimates suggest that average monthly expenditures are almost 50% lower for waiver enrollees relative to non-participants. The differences can be attributed to lower hospitalization expenses and are detected only when we control for the nonrandom selection of the program and other characteristics of patients. The OLS estimates, which assume that waiver participation is an exogenous right-hand side variable, yield the opposite conclusion. On the other hand, waiver participation does not seem to affect, positively or negatively, the survival of PWAs. Once we control for other patient characteristics, survival is equivalent in both groups of patients.
Overall, the waiver program seems to be an efficient treatment choice. 
